ALIV’s regenerative therapies cater to various fertility-based applications for both men and women, reflecting their commitment to comprehensive and preventative healthcare
ALIV - Regenerative Wellness, a pioneering regenerative healthcare startup, proudly unveils a breakthrough in fertility restoration using autologous cell fraction therapy. Dr. Sunita Tandulwadkar, a key figure at ALIV, achieved a historic milestone by facilitating the birth of India’s first ‘stem cell’ baby, who was also the world’s first for a woman at the age of 45. Following this remarkable success, ALIV has continued to lead the way with an additional 40 to 50 similar successful births, further cementing their position as pioneers in the field. This innovative treatment leverages the patient’s own cells to rejuvenate and restore ovarian function, offering new hope to those struggling with infertility and sparking global interest and adoption of similar therapeutic approaches.
Autologous cell fraction therapy starts with a painless cell extraction process performed under local anesthesia, taking only about 15 minutes. In ALIV’s state-of-the-art laboratory, cells are isolated and meticulously activated following a specialized protocol designed to stimulate natural regeneration without any manipulation or multiplication of cells. These activated cells are then precisely injected into the patient’s ovaries, initiating tissue regeneration and restoring the natural production of eggs. ALIV’s regenerative therapies cater to various fertility-based applications for both men and women, reflecting their commitment to comprehensive and preventative healthcare.
Beyond fertility restoration, autologous cell fraction therapy can rejuvenate and restore the function of various organs and tissues, offering a preventative approach to healthcare by addressing chronic lifestyle issues before they become severe. This non-invasive, non-surgical, regenerative therapy offers significant advantages over traditional treatments, therefore could be the first option before opting for invasive conventional surgeries or transplants, which may of course be unavoidable in certain cases.
Rishi Tandulwadkar, Founder of ALIV, said, “Our therapy not only utilizes the patient’s own cells, minimizing rejection risks, but also offers a minimally invasive support to traditional treatments. One notable success story involves a woman previously unable to conceive naturally, whose regenerated ovaries produced eggs that were successfully fertilized with donor sperm, leading to embryos implanted via IVF and a healthy pregnancy and birth. At ALIV, we actively seek collaboration with healthcare providers to expand treatment options and enhance patient outcomes through innovative and integrated medical solutions.”
ALIV is currently committed to sharing inspiring patient stories and disseminating informative materials to raise awareness about the potential of regenerative therapies. Through these efforts, ALIV aims to educate both the community and medical professionals, offering support programs and resources for families considering these therapies. By connecting patients with others who have undergone similar treatments, ALIV fosters a supportive community to share experiences and advice, ensuring the highest standard of care for the best possible results. ALIV firmly believes in the complementary role of regenerative therapies alongside conventional treatments, offering renewed hope to patients confronting diverse medical challenges.
Published on : 18th July, 2024